Inhibitory G proteins and their receptors: Emerging therapeutic targets for obesity and diabetes

Experimental and Molecular Medicine

Volumn 46, Issue 6, 2014, Pages

  Kimple, Michelle E ^a   Neuman, Joshua C ^b   Linnemann, Amelia K ^a   Casey, Patrick J ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Drug targets; G proteins; Insulin secretion; Obesity; Type 2 diabetes

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; CANNABINOID 1 RECEPTOR; G PROTEIN COUPLED RECEPTOR; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA I2 SUBUNIT; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA O SUBUNIT; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA Z SUBUNIT; L 798 106; MELATONIN 2 RECEPTOR; N [(5 BROMO 2 METHOXYPHENYL)SULFONYL] 3 [2 (2 NAPHTHYLMETHYL)PHENYL]ACRYLAMIDE; PERTUSSIS TOXIN; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E2; RIMONABANT; UNCLASSIFIED DRUG; YOHIMBINE; ALPHA 1 ADRENERGIC RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; PROSTAGLANDIN RECEPTOR;

ANTIDIABETIC ACTIVITY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW; SATIETY; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; GENETICS; METABOLISM;

ANIMALS; DIABETES MELLITUS, TYPE 2; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; INSULIN-SECRETING CELLS; OBESITY; RECEPTOR, MELATONIN, MT2; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, PROSTAGLANDIN;

EID: 84903706402     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2014.40     Document Type: Review

References (113)

1. Haffner SM. Epidemiology of type 2 diabetes: risk factors. Diabetes Care 1998; 21 (Suppl 3), C3-C6.
2. DeFronzo RA. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: A balanced overview. Diabetologia 1992; 35: 389-397.
3. Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 2007; 21: 1443-1455.
4. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
5. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
6. Gerich JE. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Proc 2003; 78: 447-456.
7. Meier JJ, Bonadonna RC. Role of reduced beta-cell mass versus impaired beta-cell function in the pathogenesis of type 2 diabetes. Diabetes Care 2013; 36 (Suppl 2), S113-S119.
8. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 3-19.
9. Kanat M, Mari A, Norton L, Winnier D, DeFronzo RA, Jenkinson C et al. Distinct beta-cell defects in impaired fasting glucose and impaired glucose tolerance. Diabetes 2012; 61: 447-453.
10. Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795.
11. Doyle ME, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev 2003; 55: 105-131.
12. Srivastava S, Saxena GN, Keshwani P, Gupta R. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. J Assoc Physicians India 2012; 60: 27-30.
13. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and lowdensity lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 2001; 50: 856-861.
14. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998; 6: 47-53.
15. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
16. Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsboll T. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 737-745.
17. Strathmann M, Wilkie TM, Simon MI. Diversity of the G-protein family: sequences from five additional alpha subunits in the mouse. Proc Natl Acad Sci USA 1989; 86: 7407-7409.
18. Dotson CD, Vigues S, Steinle NI, Munger SD. T1R and T2R receptors: The modulation of incretin hormones and potential targets for the treatment of type 2 diabetes mellitus. Curr Opin Investig Drugs 2010; 11: 447-454.
19. Furman B, Pyne N, Flatt P, O'Harte F. Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review. J Pharm Pharmacol 2004; 56: 1477-1492.
20. Baggio LL, Drucker DJ. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 2006; 57: 265-281.
21. Garber AJ. Incretin effects on beta-cell function, replication, and mass: The human perspective. Diabetes Care 2011; 34 (Suppl 2), S258-S263.
22. Sassmann A, Gier B, Grone HJ, Drews G, Offermanns S, Wettschureck N. The Gq/G11-mediated signaling pathway is critical for autocrine potentiation of insulin secretion in mice. J Clin Invest 2010; 120: 2184-2193.
23. Rehfeld JF. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiol (Oxf) 2011; 201: 405-411.
24. Wang Z, Thurmond DC. Mechanisms of biphasic insulin-granule exocytosis-roles of the cytoskeleton, small GTPases and SNARE proteins. J Cell Sci 2009; 122: 893-903.
25. Gallwitz B. New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. Rev Diabet Stud 2005; 2: 61-69.
26. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009; 8: 369-385.
27. Winzell MS, Ahren B. G-protein-coupled receptors and islet functionimplications for treatment of type 2 diabetes. Pharmacol Ther 2007; 116: 437-448.
28. Nisal K, Kela R, Khunti K, Davies MJ. Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus. BMC Med 2012; 10: 152.
29. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000; 43: 533-549.
30. Hsu WH, Xiang HD, Rajan AS, Boyd AE 3rd. Activation of alpha 2-adrenergic receptors decreases Ca2 influx to inhibit insulin secretion in a hamster beta-cell line: An action mediated by a guanosine triphosphate-binding protein. Endocrinology 1991; 128: 958-964.
31. Robertson RP. Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis. Diabetes 1998; 47: 1379-1383.
32. Kimple ME, Keller MP, Rabaglia MR, Pasker RL, Neuman JC, Truchan NA et al. Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- And hormone-stimulated insulin secretion. Diabetes 2013; 62: 1904-1912.
33. Kimple ME, Moss JB, Brar HK, Rosa TC, Truchan NA, Pasker RL et al. Deletion of Gaz protein protects against diet-induced glucose intolerance via expansion of b-cell mass. J Biol Chem 2012; 287: 20344-20355.
34. Robertson RP, Halter JB, Porte D Jr. A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus. J Clin Invest 1976; 57: 791-795.
35. Rosengren AH, Jokubka R, Tojjar D, Granhall C, Hansson O, Li DQ et al. Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Science 2010; 327: 217-220.
36. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000; 6: 87-97.
37. Kawamori D, Kurpad AJ, Hu J, Liew CW, Shih JL, Ford EL et al. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab 2009; 9: 350-361.
38. Kim JK, Michael MD, Previs SF, Peroni OD, Mauvais-Jarvis F, Neschen S et al. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J Clin Invest 2000; 105: 1791-1797.
39. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 367-377.
40. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998; 19: 491-503.
41. Srinivasan V, Ohta Y, Espino J, Pariente JA, Rodriguez AB, Mohamed M et al. Metabolic syndrome, its pathophysiology and the role of melatonin. Recent Pat Endocr Metab Immune Drug Discov 2013; 7: 11-25.
42. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
43. Biddinger SB, Kahn CR. From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol 2006; 68: 123-158.
44. Gadde KM, Allison DB. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation 2006; 114: 974-984.
45. Vetter ML, Dumon KR, Williams NN. Surgical treatments for obesity. Psychiatr Clin North Am 2011; 34: 881-893.
46. Katada T, Ui M. Islet-activating protein. Enhanced insulin secretion and cyclic AMP accumulation in pancreatic islets due to activation of native calcium ionophores. J Biol Chem 1979; 254: 469-479.
47. Casey PJ, Fong HK, Simon MI, Gilman AG. Gz, a guanine nucleotidebinding protein with unique biochemical properties. J Biol Chem 1990; 265: 2383-2390.
48. Kimple ME, Joseph JW, Bailey CL, Fueger PT, Hendry IA, Newgard CB et al. G{alpha}z negatively regulates insulin secretion and glucose clearance. J Biol Chem 2008; 283: 4560-4567.
49. Kimple ME, Nixon AB, Kelly P, Bailey CL, Young KH, Fields TA et al. A role for G(z) in pancreatic islet beta-cell biology. J Biol Chem 2005; 280: 31708-31713.
50. Zhao Y, Fang Q, Straub SG, Lindau M, Sharp GW. Hormonal inhibition of endocytosis: novel roles for noradrenaline and G protein G(z). J Physiol 2010; 588: 3499-3509.
51. Matsuoka M, Itoh H, Kozasa T, Kaziro Y. Sequence analysis of cDNA and genomic DNA for a putative pertussis toxin-insensitive guanine nucleotide-binding regulatory protein alpha subunit. Proc Natl Acad Sci USA 1988; 85: 5384-5388.
52. Garibay JL, Kozasa T, Itoh H, Tsukamoto T, Matsuoka M, Kaziro Y. Analysis by mRNA levels of the expression of six G protein alpha-subunit genes in mammalian cells and tissues. Biochim Biophys Acta 1991; 1094: 193-199.
53. Lang J. Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion. Eur J Biochem 1999; 259: 3-17.
54. Zhao Y, Fang Q, Straub SG, Lindau M, Sharp GW. Noradrenaline inhibits exocytosis via the G protein betagamma subunit and refilling of the readily releasable granule pool via the alpha(i1/2) subunit. J Physiol 2010; 588: 3485-3498.
55. Moxham CM, Malbon CC. Insulin action impaired by deficiency of the G-protein subunit G ialpha2. Nature 1996; 379: 840-844.
56. Chen JF, Guo JH, Moxham CM, Wang HY, Malbon CC. Conditional, tissuespecific expression of Q205L G alpha i2 in vivo mimics insulin action. J Mol Med 1997; 75: 283-289.
57. Song X, Zheng X, Malbon CC, Wang H. Galpha i2 enhances in vivo activation of and insulin signaling to GLUT4. J Biol Chem 2001; 276: 34651-34658.
58. Valenzuela D, Han X, Mende U, Fankhauser C, Mashimo H, Huang P et al. Galpha(o) is necessary for muscarinic regulation of Ca2 channels in mouse heart. Proc Natl Acad Sci USA 1997; 94: 1727-1732.
59. Wang Y, Park S, Bajpayee NS, Nagaoka Y, Boulay G, Birnbaumer L et al. Augmented glucose-induced insulin release in mice lacking G(o2), but not G(o1) or G(i) proteins. Proc Natl Acad Sci USA 2011; 108: 1693-1698.
60. Ho MK, Wong YH. G(z) signaling: emerging divergence from G(i) signaling. Oncogene 2001; 20: 1615-1625.
61. Ayoub MA, Damian M, Gespach C, Ferrandis E, Lavergne O, De Wever, O et al. Inhibition of heterotrimeric G protein signaling by a small molecule acting on Galpha subunit. J Biol Chem 2009; 284: 29136-29145.
62. Holler C, Freissmuth M, Nanoff C. G proteins as drug targets. Cell Mol Life Sci 1999; 55: 257-270.
63. Kimple AJ, Bosch DE, Giguere PM, Siderovski DP. Regulators of G-protein signaling and their Galpha substrates: promises and challenges in their use as drug discovery targets. Pharmacol Rev 2011; 63: 728-749.
64. Marti-Solano M, Guixa-Gonzalez R, Sanz F, Pastor M, Selent J. Novel insights into biased agonism at G protein-coupled receptors and their potential for drug design. Curr Pharm Des 2013; 19: 5156-5166.
65. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 2008; 31 (Suppl 2), S161-S164.
66. Gordillo-Moscoso A, Ruiz E, Carnero M, Reguillo F, Rodriguez E, Tejerina T et al. Relationship between serum levels of triglycerides and vascular inflammation, measured as COX-2, in arteries from diabetic patients: A translational study. Lipids Health Dis 2013; 12: 62.
67. Vaarala O, Yki-Jarvinen H. Diabetes: should we treat infection or inflammation to prevent T2DM? Nat Rev Endocrinol 2012; 8: 323-325.
68. Hwang D. Fatty acids and immune responses-a new perspective in searching for clues to mechanism. Annu Rev Nutr 2000; 20: 431-456.
69. Luo P, Wang MH. Eicosanoids, beta-cell function, and diabetes. Prostaglandins Other Lipid Mediat 2011; 95: 1-10.
70. Metz SA, McRae JR, Robertson RP. Hypothesis: prostaglandins mediate defective glucose recognition in diabetes mellitus. Prostaglandins Med 1980; 4: 247-254.
71. Robertson RP, Chen M. A role for prostaglandin E in defective insulin secretion and carbohydrate intolerance in diabetes mellitus. J Clin Invest 1977; 60: 747-753.
72. Robertson RP. Eicosanoids as pluripotential modulators of pancreatic islet function. Diabetes 1988; 37: 367-370.
73. American Diabetes Association Task Force for Writing Nutrition P, Recommendations for the Management of D, Related C. American Diabetes Association position statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. J Am Diet Assoc 2002; 102: 109-118.
74. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood) 2008; 233: 674-688.
75. Wu JH, Micha R, Imamura F, Pan A, Biggs ML, Ajaz O et al. Omega-3 fatty acids and incident type 2 diabetes: A systematic review and meta-analysis. Br J Nutr 2012; 107(Suppl 2), S214-S227.
76. Bellenger J, Bellenger S, Bataille A, Massey KA, Nicolaou A, Rialland M et al. High pancreatic n-3 fatty acids prevent STZ-induced diabetes in fat-1 mice: inflammatory pathway inhibition. Diabetes 2011; 60: 1090-1099.
77. Wei D, Li J, Shen M, Jia W, Chen N, Chen T et al. Cellular production of n-3 PUFAs and reduction of n-6-to-n-3 ratios in the pancreatic beta-cells and islets enhance insulin secretion and confer protection against cytokine-induced cell death. Diabetes 2010; 59: 471-478.
78. Sorli CH, Zhang HJ, Armstrong MB, Rajotte RV, Maclouf J, Robertson RP. Basal expression of cyclooxygenase-2 and nuclear factor-interleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet. Proc Natl Acad Sci USA 1998; 95: 1788-1793.
79. Fujita H, Kakei M, Fujishima H, Morii T, Yamada Y, Qi Z et al. Effect of selective cyclooxygenase-2 (COX-2) inhibitor treatment on glucosestimulated insulin secretion in C57BL/6 mice. Biochem Biophys Res Commun 2007; 363: 37-43.
80. Persaud SJ, Burns CJ, Belin VD, Jones PM. Glucose-induced regulation of COX-2 expression in human islets of Langerhans. Diabetes 2004; 53 (Suppl 1), S190-S192.
81. Shanmugam N, Todorov IT, Nair I, Omori K, Reddy MA, Natarajan R. Increased expression of cyclooxygenase-2 in human pancreatic islets treated with high glucose or ligands of the advanced glycation endproduct- specific receptor (AGER), and in islets from diabetic mice. Diabetologia 2006; 49: 100-107.
82. Yang F, Bleich D. Transcriptional regulation of cyclooxygenase-2 gene in pancreatic beta-cells. J Biol Chem 2004; 279: 35403-35411.
83. Becker RC. COX-2 inhibitors. Tex Heart Inst J 2005; 32: 380-383.
84. Smith CJ, McKay GA, Fisher M. Diabetes, colorectal cancer and cyclooxygenase 2 inhibition. Int J Clin Pract 2008; 62: 810-815.
85. Gilgore SG, Rupp JJ. The long-term response of diabetes mellitus to salicylate therapy: report of a case. JAMA 1962; 180: 65-66.
86. Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA et al. Salicylate (salsalate) in patients with type 2 diabetes: A randomized trial. Ann Intern Med 2013; 159: 1-12.
87. Zhang J, Zou F, Tang J, Zhang Q, Gong Y, Wang Q et al. Cyclooxygenase-2- derived prostaglandin E2 promotes injury-induced vascular neointimal hyperplasia through the E-prostanoid 3 receptor. Circ Res 2013; 113: 104-114.
88. Chen L, Miao Y, Zhang Y, Dou D, Liu L, Tian X et al. Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility. Arterioscler Thromb Vasc Biol 2012; 32: 3024-3032.
89. Sanchez-Alavez M, Klein I, Brownell SE, Tabarean IV, Davis CN, Conti B et al. Night eating and obesity in the EP3R-deficient mouse. Proc Natl Acad Sci USA 2007; 104: 3009-3014.
90. Ram A, Pandey HP, Matsumura H, Kasahara-Orita K, Nakajima T, Takahata R et al. CSF levels of prostaglandins, especially the level of prostaglandin D2, are correlated with increasing propensity towards sleep in rats. Brain Res 1997; 751: 81-89.
91. Dumont I, Peri KG, Hardy P, Hou X, Martinez-Bermudez AK, Molotchnikoff S et al. PGE2, via EP3 receptors, regulates brain nitric oxide synthase in the perinatal period. Am J Physiol 1998; 275: R1812-R1821.
92. Tilly P, Charles AL, Ludwig S, Slimani F, Gross S, Meilhac O et al. Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence. Cardiovasc Res 2014; 101: 482-491.
93. Robertson RP, Beiter HL, Porte D Jr. Abnormal alpha-adrenergic mechanisms in diabetes mellitus. Lancet 1973; 1: 370.
94. Rosengren AH, Braun M, Mahdi T, Andersson SA, Travers ME, Shigeto M et al. Reduced insulin exocytosis in human pancreatic beta-cells with gene variants linked to type 2 diabetes. Diabetes 2012; 61: 1726-1733.
95. Talmud PJ, Cooper JA, Gaunt T, Holmes MV, Shah S, Palmen J et al. Variants of ADRA2A are associated with fasting glucose, blood pressure, body mass index and type 2 diabetes risk: meta-analysis of four prospective studies. Diabetologia 2011; 54: 1710-1719.
96. Kurnik D, Muszkat M, Li C, Sofowora GG, Friedman EA, Scheinin M et al. Genetic variations in the alpha(2A)-adrenoreceptor are associated with blood pressure response to the agonist dexmedetomidine. Circ Cardiovasc Genet 2011; 4: 179-187.
97. Henry RR. Type 2 diabetes care: The role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention. Am J Med 1998; 105: 20-26.
98. Tayel SI, Khader HF, El-Helbawy NG, Ibrahim WA. Association of deletion allele of insertion/deletion polymorphism in alpha2B adrenoceptor gene and hypertension with or without type 2 diabetes mellitus. Appl Clin Genet 2012; 5: 111-118.
99. Mulder H, Nagorny CL, Lyssenko V, Groop L. Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene. Diabetologia 2009; 52: 1240-1249.
100. Peschke E. Melatonin, endocrine pancreas and diabetes. J Pineal Res 2008; 44: 26-40.
101. Faria JA, Kinote A, Ignacio-Souza LM, de Araujo TM, Razolli DS, Doneda DL et al. Melatonin acts through MT1/MT2 receptors to activate hypothalamic Akt and suppress hepatic gluconeogenesis in rats. Am J Physiol Endocrinol Metab 2013; 305: E230-E242.
102. Zanuto R, Siqueira-Filho MA, Caperuto LC, Bacurau RF, Hirata E, Peliciari-Garcia RA et al. Melatonin improves insulin sensitivity independently of weight loss in old obese rats. J Pineal Res 2013; 55: 156-165.
103. McMullan CJ, Schernhammer ES, Rimm EB, Hu FB, Forman JP. Melatonin secretion and the incidence of type 2 diabetes. JAMA 2013; 309: 1388-1396.
104. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, Sparso T, Holmkvist J, Marchand M et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 2009; 41: 89-94.
105. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet 2009; 41: 77-81.
106. Huopio H, Cederberg H, Vangipurapu J, Hakkarainen H, Paakkonen M, Kuulasmaa T et al. Association of risk variants for type 2 diabetes and hyperglycemia with gestational diabetes. Eur J Endocrinol 2013; 169: 291-297.
107. Zhang C, Bao W, Rong Y, Yang H, Bowers K, Yeung E et al. Genetic variants and the risk of gestational diabetes mellitus: A systematic review. Hum Reprod Update 2013; 19: 376-390.
108. Bilkei-Gorzo A. The endocannabinoid system in normal and pathological brain ageing. Philos Trans R Soc Lond B Biol Sci 2012; 367: 3326-3341.
109. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal, LF Group RI-DS. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 2006; 368: 1660-1672.
110. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease-successes and failures. FEBS J 2013; 280: 1918-1943.
111. LoVerme, J, Duranti A, Tontini A, Spadoni G, Mor M, Rivara S et al. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett 2009; 19: 639-643.
112. Cluny NL, Vemuri VK, Chambers AP, Limebeer CL, Bedard H, Wood JT et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 2010; 161: 629-642.
113. Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010; 120: 2953-2966.